IDEAYA reports Q2 2026 results, darovasertib trial hits primary endpoint
OptimUM-02 met its progression-free survival goal in metastatic uveal melanoma as IDEAYA files an NDA under FDA's real-time review program, backed by $1.24 billion in cash.
SEC filing